Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].

Voprosy onkologii - 1 Jan 2014

Gorodnova T V, Maksimov S Ia, Guseĭnov K D, Imianitov E N

Abstract excerpt

The purpose of this study was to examine the clinical significance of mutations in BRCA1/2 in the formation of response to neoadjuvant platinum-based chemotherapy for ovarian cancer (OC). All patients who had had neoadjuvant chemotherapy (NCT) in our Institute from January 2000 till January 2013 were tested for carrier of mutations in BRCA1/2. In accordance with the BRCA-status we formed two groups--a group with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Chemotherapy, Adjuvant

Share to Neoadjuvant Therapy

Share to Ovarian Neoplasms

Share to Platinum Compounds

Share to Treatment Outcome

Source

Identifiers

PMID: 25033687

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Effectiveness of platinum-based chemotherapy in ovarian cancer patients with BRCA1/2 mutations].PMID 25033687Read ↗

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.Semantic proximity Read ↗

[Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].Semantic proximity Read ↗

[Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].Semantic proximity Read ↗

[Medical treatment options in BRCA-associated cancers].Semantic proximity Read ↗

BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.Semantic proximity Read ↗

Effects of neoadjuvant chemotherapy in ovarian cancer patients with different germline BRCA1/2 mutational status: A retrospective studySemantic proximity Read ↗

Germline BRCA, Chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancerSemantic proximity Read ↗

[Clinical features and disease course in patients with BRCA1-dependent ovarian cancer].Semantic proximity Read ↗

Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.Semantic proximity Read ↗

BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.Semantic proximity Read ↗

High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutationSemantic proximity Read ↗

BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.